Methyl 1-thio-D-galactopyranoside | 169532-18-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Methyl 1-thio-D-galactopyranoside
• 英文别名: (2R,3R,4S,5R)-2-(hydroxymethyl)-6-methylsulfanyloxane-3,4,5-triol
• CAS: 169532-18-7
• 化学式: C₇H₁₄O₅S
• 分子量: 210.25
• InChiKey: LZFNFLTVAMOOPJ-TVPFVARWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• [EN] RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF<br/>[FR] MOLÉCULES LIBÉRANT DU RUTHÉNIUM-MONOXYDE DE CARBONE ET UTILISATIONS DE CELLES-CI
  申请人：ALFAMA INC

  公开号：WO2013013179A1

  公开（公告）日：2013-01-24

  The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute respiratory distress syndrome, which optionally may be associated with a malaria infection.

  本发明提供了式（I）的新型钌化合物：或其盐，异构体，水合物或溶剂化物，或其组合物；其中E，R1，R2，R3，R4，R5，X1和X2如本文所定义，并提供其制备的药物组合物。还提供了使用和治疗的方法。已经发现这些化合物在治疗疟疾感染方面非常有用。这些化合物也可能在治疗炎症病症方面有用，例如急性肺损伤和急性呼吸窘迫综合症，这些病症可能与疟疾感染有关。
• RUTHENIUM CARBON MONOXIDE RELEASING MOLECULES AND USES THEREOF
  申请人：Alfama, Inc.

  公开号：US20150322105A1

  公开（公告）日：2015-11-12

  The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , and X 2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute resipiratory distress syndrome, which optionally may be associated with a malaria infection.

  本发明提供了式（I）的新型钌化合物：或其盐，异构体，水合物或溶剂化物，或其组合物；其中E，R1，R2，R3，R4，R5，X1和X2如本文所定义，并提供其制药组合物。还提供了使用和治疗方法。已发现这些化合物在治疗疟疾感染方面非常有用。这些化合物在治疗炎症病症方面也可能非常有用，例如急性肺损伤和急性呼吸窘迫综合症，这些病症可以选择性地与疟疾感染有关。
• PRODUCTION OF HUMAN BASIC FGF MUTEIN
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0506963A1

  公开（公告）日：1992-10-07
• EP0530322A4
  申请人：——

  公开号：EP0530322A4

  公开（公告）日：1994-06-29
• NOVEL AND IMPROVED METHOD FOR DETERMINATION OF E. COLI IN WATER
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：EP0530322A1

  公开（公告）日：1993-03-10